Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us Donate
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
    All Public Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • KFF Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Data for Deportation
  • Home Births
  • Hantavirus News Roundup
  • RFK Jr.
  • AI in Healthcare

WHAT'S NEW

  • Medicaid Data for Deportation
  • Home Births
  • Hantavirus News Roundup
  • RFK Jr.
  • AI in Healthcare

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Wednesday, Sep 7 2011

TB Vaccine Candidate Shows Early Potential In Mice

Scientists at the Howard Hughes Medical Institute (HHMI), Albert Einstein College of Medicine and Colorado State University report in the September 4 issue of Nature Medicine that "[a] potential vaccine against tuberculosis [TB] has been found to completely eliminate tuberculosis bacteria from infected tissues in some mice," according to a HHMI press release. "The vaccine was created with a strain of bacteria that, due to the absence of a few genes, are unable to avoid its host's first-line immune response," the release states, adding, "Once this first-line defense has been activated, it triggers the more specific immune response that can protect against future infections" (9/4). A spokesperson for the campaign group TB Alert told BBC News, "These are interesting experiments but it is too early to tell what impact they will have on the development of a safe and effective vaccine," the news service reports (Gallagher, 9/4).
This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Thursday, May 14
  • Wednesday, May 13
  • Tuesday, May 12
  • Monday, May 11
  • Friday, May 8
  • Thursday, May 7
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Donate
  • Staff
  • Republish Our Content
  • Contact Us

Follow Us

  • Instagram
  • YouTube
  • LinkedIn
  • Facebook
  • X
  • Bluesky
  • TikTok
  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 KFF